tiprankstipranks
Neogen Corp (NEOG)
NASDAQ:NEOG
US Market
Want to see NEOG full AI Analyst Report?

Neogen (NEOG) Earnings Dates, Call Summary & Reports

269 Followers

Earnings Data

Report Date
Jul 28, 2026
Before Open (Confirmed)
Period Ending
2026 (Q4)
Consensus EPS Forecast
0.06
Last Year’s EPS
-2.82
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2026
Earnings Call Date:Apr 09, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presented a balanced picture: solid execution and margin improvement in Food Safety, positive free cash flow, progress on the Petrifilm manufacturing transition, and a clear multi-pronged transformation plan. However, notable near-term challenges remain—most prominently supplier-related disruptions in Animal Safety, logistics/freight inflation, FX headwinds, inventory legacy risks and a still-elevated debt position. Management is taking concrete actions (supplier qualification, operational centralization, targeted CapEx and a planned divestiture) that support medium-term improvement, but near-term headwinds temper upside.
Company Guidance
Management raised fiscal 2026 revenue guidance to $857–$860 million while maintaining adjusted EBITDA guidance of $175 million; Q3 revenue was $211.2 million (core +0.1%), with Food Safety $156.7M (core +4%) and Animal Safety $54.5M (core −8.7%). Key margin and profitability metrics: reported gross margin 46.9%, adjusted gross margin 51.7%, adjusted EBITDA $48.2M (22.8% margin, ~110 bps sequential improvement), adjusted net income $19.4M and adjusted EPS $0.09; free cash flow was $11.1M in Q3 and is positive year-to-date. Balance sheet and portfolio items include $800M gross debt (68% fixed), $159.9M cash, and an announced genomics divestiture for $160M (expected net proceeds ≈$140M, closing expected Q2 FY27) intended to lower net debt/adjusted EBITDA to below 3x by end of calendar 2026. Management warned of diminishing FX tailwinds (≈40% of revenue non‑USD), ongoing Animal Safety supplier headwinds into Q4, incremental freight/transport costs of about $1.5M per quarter (high single- to low double‑digit % increases), $40M annual plastics OEM spend with 6–9 months inventory, Petrifilm manufacturing transition on track for November 2026 (3M agreement through August 2027), and noted that transformation‑related spend (including a new Petrifilm R&D line) will be treated as temporary and excluded from adjusted results.
Third Quarter Revenue and Core Growth
Q3 revenue of $211.2 million with core revenue growth of +0.1% year-over-year; demonstrates stability in a mixed market environment.
Food Safety Segment Strength
Food Safety revenue of $156.7 million, delivering 4% core growth year-over-year; led by indicator testing (+11%) and strong pathogen test kit performance.
Improved Profitability Metrics
Adjusted EBITDA of $48.2 million with a margin of 22.8%, an improvement of ~110 basis points sequentially; adjusted gross margin of 51.7% and reported gross margin of 46.9% (essentially flat year-over-year excluding one-time costs).
Positive Free Cash Flow and Balance Sheet Actions
Free cash flow in Q3 was $11.1 million and free cash flow is positive year-to-date; announced sale of genomics business for $160 million (expected net proceeds ~$140M) to reduce debt and target net debt/adjusted EBITDA below 3x by end of 2026.
Petrifilm Manufacturing Transition Progress
On-schedule transition with full validation completed for 100% of production equipment and SKU validations underway; in-house manufacturing expected to improve contribution margin on incremental Petrifilm revenue and enable custom SKUs and R&D prototyping (research-scale R&D line funded Q4 FY26).
Cost Discipline and Operating Expense Improvement
Adjusted operating expenses declined ~9% sequentially versus Q2, driven by cost control and restructuring actions; company emphasizing further OpEx scrutiny and investments targeted at value-creating transformation.
Strategic Transformation Initiatives
Clear transformation plan: (1) commercial prowess (new global commercial leadership and solutions-based selling), (2) high-impact innovation (organic and licensed tech, Petrifilm SKU expansion), and (3) operational efficiency (S&OP, AI-enabled planning, supplier controls).
Market Dynamics Supporting Long-Term Demand
Industry recall activity rose ~15% from 2024 to 2025 and FDA recalled volume more than doubled year-over-year, reinforcing structural demand for reliable food-safety solutions and Neogen's market relevance.

Neogen (NEOG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

NEOG Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 28, 2026
2026 (Q4)
0.06 / -
-2.82
Apr 09, 2026
2026 (Q3)
0.06 / 0.09
-0.05280.00% (+0.14)
Jan 08, 2026
2026 (Q2)
0.06 / 0.10
-2.1104.76% (+2.20)
Oct 09, 2025
2026 (Q1)
-0.07 / 0.04
-0.06166.67% (+0.10)
Jul 29, 2025
2025 (Q4)
-0.05 / -2.82
-0.02-14000.00% (-2.80)
Apr 09, 2025
2025 (Q3)
-0.02 / -0.05
-0.01-400.00% (-0.04)
Jan 10, 2025
2025 (Q2)
-0.01 / -2.10
-0.02-10400.00% (-2.08)
Oct 10, 2024
2025 (Q1)
-0.03 / -0.06
0.01-700.00% (-0.07)
Jul 30, 2024
2024 (Q4)
-0.01 / -0.02
0.03-166.67% (-0.05)
Apr 09, 2024
2024 (Q3)
0.01 / -0.01
0.04-125.00% (-0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

NEOG Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 09, 2026
$10.34$10.04-2.95%
Jan 08, 2026
$7.38$9.71+31.57%
Oct 09, 2025
$5.82$6.78+16.49%
Jul 29, 2025
$5.42$4.83-10.89%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neogen Corp (NEOG) report earnings?
Neogen Corp (NEOG) is schdueled to report earning on Jul 28, 2026, Before Open (Confirmed).
    What is Neogen Corp (NEOG) earnings time?
    Neogen Corp (NEOG) earnings time is at Jul 28, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is NEOG EPS forecast?
          NEOG EPS forecast for the fiscal quarter 2026 (Q4) is 0.06.